Biologics have been a great advance in therapeutics, but at great cost. Although biologics account for less than 1% of all prescriptions in the USA, they account for 28% percent of the cost of prescribed medications.
On October 1st, your coding memory will be getting a big and unwelcomed upgrade.
Even if the goverment shuts down, ICD-10 implementation goes forward.
Below are several sources to review what's ahead and what you should be focused on at this point.
Study 329 was published in 2001, and became a pivotal study for the anti-depressant drug Paxil (paroxetine). In 2002, over 2 million prescriptions were written for Paxil.
Dozens of medical societies pressed the Centers for Medicare and Medicaid Services (CMS) to temporarily halt implementation of the final stage of Meaningful Use, a program that rewards and penalizes clinicians based on how effectively they use electronic medical records.
October is Raynaud's Awareness Month according to the Raynaud's Association (http://www.raynauds.org), and a whopping 80 percent of sufferers are not aware they have the disorder and do not seek treatment.
Knee replacement surgery is on the rise, and so is the cost.
A recent article by Dr. Joseph Eastern of the Pediatric News Network addressed an issue that confronts all practitioners - how do you handle email from patients?
PLOS has reported the results of the 2012 US National Health Interview Survey that focuses on fibromyalgia.
Biosimilars are rapidly growing. Many of these will have their first introduction to countries outside of the USA. There is concern whether biosimilars will provide identical pharmacodynamics, biological function, efficacy and toxicity to reference products, both in the short and long term.
A recent article from Healio.com reviewed the FDA’s Pregnancy and Lactation Labeling Rule (PLLR) that became effective June 30th.
Long-term management of osteoporosis can be challenging, and given the increasing number of choices, the best sequence of drug use has not been addressed adequately.
Secukinumab (Cosentyx) is an anti-IL-17 monoclonal antibody currently approved for use in moderate to severe psoriasis. It has also been studied in psoriatic arthritis (PsA) and shown to be safe and effective.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
